Today we announced additional one-year data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for DM1. We're pleased to share these results at both #WMS2026 and #AANEM2026. Read more: bit.ly/4iQUleP

We’re in San Antonio for the Neuromuscular Study Group (NMSG) Scientific Meeting sharing preclinical data from our portfolio of investigational DMD therapies. Looking forward to connecting!

Vertex Pharmaceuticals founder Dr. Joshua Boger sat down with us and shared his take on building great companies: "It's never about the technology... tell me what you're going to do with it." Tech gets you in. Culture and ownership win.

September is a busy month for Dyne as we join the healthcare investment community at three upcoming conferences. Learn more about our participation and fireside chats: bit.ly/3Uwl5ah

Dyne Q2 2026 highlights: -FDA accepted our BLA for z-rostudirsen (exon 51 DMD), Priority Review granted, PDUFA date Jan 21, 2027 -ACHIEVE REC enrollment complete (z-basivarsen, DM1) -IND cleared for DYNE-302 (FSHD) -Cash runway into Q2 2028 Full results: bit.ly/4fHRFga

The FDA has cleared our Investigational New Drug (IND) application to begin our Phase I clinical trial in FSHD.     Learn more: bit.ly/4fCmmmT

Dyne Announces FDA Acceptance of the Biologics License Application (BLA) for z-rostudirsen in Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping. Read the press release: bit.ly/4gMtv6D

Congratulations to our #Dynamos who were recently promoted! Your passion and dedication to our patients make this team stronger every day. Here's to the impact still ahead as we work to help people living with genetically driven neuromuscular diseases.

Today we welcomed Barry Greene to Dyne’s Board of Directors. Barry’s strong biopharmaceutical experience spanning nearly three decades will be valuable as we continue progressing toward potential commercialization. Read more: bit.ly/43PoMJC

Great conversation with Adam Koppel. Conviction. Clarity. Empathy. Resilience. Adam reminded us that success in biotech is not just about the science. It is about the strength and credibility of the teams working to deliver for patients.

Dyne announces completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial evaluating z-basivarsen in DM1.    See the full press release here: bit.ly/4akMNM3

In the days ahead, we look forward to engaging with the investment community and discussing our neuromuscular programs designed to deliver functional improvement. bit.ly/4dmTldT

Dyne announces BLA submission for z-rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD). See the full press release here: bit.ly/3PBmTwF

Today we announced initiation of the Phase 3 confirmatory FORZETTO trial evaluating z-rostudirsen in exon 51 DMD. See the full press release here: bit.ly/4dYxmKT

As we head toward our first potential commercial launch in DMD, Ramona Sequeira joined our FORCEs in Biotech series to share insights on scaling effectively. Key takeaways: • Fix > Analyze • Focus on "how," not "why not" • Be authentic & timely We’re ready.

Today we announced our Q1 2026 financial results highlighting progress across our pipeline. See the press release here bit.ly/3RxC4Y5

Next month, we’ll be presenting preclinical data in an oral session at @ASGCT annual meeting highlighting the ability of our FORCE™ platform to drive robust activity in the central nervous system. Learn more: bit.ly/4uhaVHh #ASGCT2026

Looking forward to #AMCP2026 with @amcporg where we’ll be presenting three posters across our DMD and DM1 programs. Full update here: bit.ly/4sGyTuV

Our new claims study in @JME_Journal shows the true complexity of DM1. Data reveal multi-organ decline, increased healthcare use, and serious cardiac and pulmonary risks. The burden on people with DM1 and caregivers is significant. We need earlier care. bit.ly/4rOXHQs

Grateful for the conversations, science shared and chance to connect with so many working to advance care for people living with neuromuscular diseases. #MDAConference